CORRECTION

Correction: Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer

The *PLOS ONE* Staff

In the article title, “Lap atinib” should be displayed as “Lapatinib.” The correct title is: Yes1 signaling mediates the resistance to Trastuzumab/Lapatinib in breast cancer. The correct citation is: Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, et al. (2017) Yes1 signaling mediates the resistance to Trastuzumab/Lapatinib in breast cancer. PLoS ONE 12(2): e0171356. doi:[10.1371/journal.pone.0171356](https://doi.org/10.1371/journal.pone.0171356). The publisher apologizes for the error.

Reference

1. Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, et al. (2017) Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS ONE 12(2): e0171356. doi:[10.1371/journal.pone.0171356](https://doi.org/10.1371/journal.pone.0171356) PMID: [28158234](https://pubmed.ncbi.nlm.nih.gov/28158234/)

OPEN ACCESS

Citation: The *PLOS ONE* Staff (2017) Correction: Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS ONE 12(3): e0174493. <https://doi.org/10.1371/journal.pone.0174493>

Published: March 16, 2017

Copyright: © 2017 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.